Health Care & Life Sciences » Biotechnology | Benitec Biopharma Ltd.

Benitec Biopharma Ltd. | Cash Flow

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Net Income before Extraordinaries
7,039.10
11,509.00
24,778.00
5,690.00
11,640.00
Depreciation, Depletion & Amortization
12.80
97.00
290.00
217.00
194.00
Other Funds
363.90
936.00
4,612.00
3,591.00
353.00
Funds from Operations
6,662.40
10,476.00
19,876.00
9,064.00
11,093.00
Changes in Working Capital
2,607.90
784.00
332.00
760.00
1,299.00
Net Operating Cash Flow
9,270.30
9,692.00
20,208.00
8,304.00
9,794.00
Capital Expenditures
32.40
505.00
342.00
171.00
83.00
Sale of Fixed Assets & Businesses
-
-
-
-
2.00
Purchase/Sale of Investments
-
-
-
131.00
-
Net Investing Cash Flow
32.40
505.00
342.00
302.00
147.00
Net Financing Cash Flow
39,075.60
52.00
17,510.00
7,939.00
8,507.00
Net Change in Cash
29,771.90
9,572.00
3,557.00
855.00
1,290.00
Free Cash Flow
9,302.70
10,197.00
20,550.00
8,475.00
9,877.00
Change in Capital Stock
39,075.60
52.00
17,510.00
7,939.00
8,507.00
Exchange Rate Effect
1.00
573.00
517.00
188.00
144.00
Other Uses
-
-
-
-
66.00

About Benitec Biopharma

View Profile
Address
99 Mount Street
North Sydney New South Wales (NSW) 2060
Australia
Employees -
Website http://www.benitec.com
Updated 07/08/2019
Benitec Biopharma Ltd. engages in the development of therapeutics based on patented gene silencing technology called ddRNAi. It develops treatments for chronic and life threatening human conditions, such as oculopharyngeal muscular dystrophy, oncology, wet age-related macular degeneration, and hepatitis B. It operates through the Australia and USA geographical segments.